Search
for

    Sort by

    Community Join

    450-480 / 1000+ results

      community Pyrilutamide Phase 3 on its way

      in Treatment  128 upvotes 4 years ago
      Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.

      community What to look Forward to in 2025

      in Research/Science  20 upvotes 1 year ago
      Hair loss treatments are advancing, with Coegin Pharma's FOL005 expected this year and Breezula potentially later. Pyrilutamide is available but not very effective, while Kintor's products face skepticism; traditional treatments like finasteride and minoxidil remain dominant.

      community What do you think about pyrilutamide?

      in Product  5 upvotes 1 year ago
      Pyrilutamide is being discussed as a potential hair loss treatment, but opinions are mixed, with some users skeptical about its effectiveness and the company's credibility. Some users report combining pyrilutamide with other treatments like dutasteride and microneedling, noting improvements, while others remain doubtful.

      community Has anybody tried RU58841 and pyrilutamide together?

      in Chat  10 upvotes 10 months ago
      RU58841 and pyrilutamide are being discussed as potential hair loss treatments, with some users reporting side effects. There is interest in these treatments as alternatives to 5ar inhibitors and oral minoxidil due to concerns about safety and side effects.

      community Pyrilutamide just launched internationally, and all you're doing is hating

      in Product 1 year ago
      The post and conversation are about the high cost and skepticism surrounding pyrilutamide as a hair loss treatment, with comparisons to minoxidil, finasteride, and RU58841. The original poster defends pyrilutamide's effectiveness and criticizes others for dismissing it without proper understanding.

      community Petition Alert: Let's Get PP405 Phase 3 Trials in Germany by 2026!

      in Research/Science  57 upvotes 11 months ago
      A user is advocating for Phase 3 trials of the hair loss treatment PP405 to be conducted in Germany, citing benefits like a diverse patient base and faster access for European patients. Despite skepticism about the petition's influence, the user believes it can demonstrate significant interest and potentially influence strategic decisions.

      community Follicum releases some data from previous phase 2a trial

      in Research/Science  14 upvotes 3 years ago
      Follicum discovered that their drug FOL-005 increased hair count by 12 hairs per cm2 in patients with less than 255 hairs per cm2 and is planning a phase 2b trial. They are currently fundraising for the trial, and the drug may also be effective for women.

      community Compounded topicals

      in Female  6 upvotes 5 years ago
      BionicBell discussed using Bimatoprost, a medication typically for eyelash growth, for hair loss and mentioned a compounding pharmacy that can mix it with other ingredients like minoxidil and finasteride. They are seeking advice on using topical finasteride for female pattern baldness and are considering a custom foam combination to maximize hair growth results.

      community Locklabs + Dutasteride Formula

      in Treatment  1 upvotes 5 months ago
      The conversation discusses the effectiveness and value of a Locklabs pill containing finasteride, minoxidil, biotin, and a low dose of dutasteride for hair loss. The user is uncertain if the .1mg dutasteride dosage is sufficient and worth the cost.

      community Hairfibers: Toppik vs Boldify vs Surethik?

      in Product  6 upvotes 3 years ago
      User discovered hair fibers, tried Toppik but concerned about ingredients. Considering Boldify (cotton-based, cheaper) and Surethik (keratin-based) as better options.

      community How's your progress on kx-826 (pyrilutamide)?

      in Treatment  11 upvotes 1 month ago
      People are discussing their experiences with kx-826 (pyrilutamide) for hair loss, using concentrations of 0.5% and 0.9%. They are sharing personal results and progress with this treatment.

      community Possibility of updates or more information on the pp405

      in Chat  19 upvotes 7 months ago
      The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

      community 2nd day on pyrilutamide - what I noticed so far

      in Treatment  7 upvotes 3 years ago
      The user started using a hair loss treatment called pyrilutamide and experienced mild chest discomfort and tightness, similar to previous side effects from RU58841. They plan to reduce the dosage due to these side effects and will provide an update on the results in 1-2 months.

      community Is Pyrilutamide the real deal and if so when will it actually be available?

      in Chat  21 upvotes 3 years ago
      Pyrilutamide, a potential hair loss treatment that is currently in development and may be available soon; an androgen receptor degrader which is also being developed as a potential treatment for hair loss; and the comparison between Pyrilutamide, finasteride, minoxidil, and RU58841.

      community RU58841 vehicle penetration (Study for minoxidil)

      in Treatment  12 upvotes 3 years ago
      The user mixes their own RU58841 solution and found that increasing the ethanol content improved absorption and reduced scalp itching. A study on minoxidil showed that penetration increased with higher ethanol concentrations, reaching maximum penetration at 90% ethanol.

      community HMI-115 question about potential earliest access

      in Research/Science  10 upvotes 3 years ago
      Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.